- Patent Number:
10689,418
- Appl. No:
16/065078
- Application Filed:
December 22, 2016
- Abstract:
The invention provides a series of peptides with N-methyl-D-aspartate (NMDA) receptor modulating activity. Specifically it contains two synthetic peptides acting as ion inflow antagonists through the NMDA receptor with specificity GluN2B and GluN2A NMDA receptor subunits and a peptide having agonist activity regarding the NMDA receptor in rat hippocampal neuron cultures.
- Inventors:
UNIVERSIDAD NACIONAL DE COLOMBIA (Bogotá, CO)
- Assignees:
Universidad Nacional de Colombia (Bogota, CO)
- Claim:
1. An artificially designed 17 amino acid-long peptide, wherein said peptide has the following hydrophilic amino acid sequence: GEDDLQDNQDLIRDKSN (SEQ ID NO: 2); said peptide having a molecular formula of C 78 H 127 N 25 O 35 ; a molecular weight of 1975.03 g/Mol; an isoelectric point of 3.90 and an average hydropathicity (GRAVY) of −1.912.
- Claim:
2. The peptide, according to claim 1 , wherein said peptide has selective antagonism towards the NMDA receptor GluN2B subunit.
- Claim:
3. The peptide, according to claim 1 , wherein said peptide is a membrane ionic permeability modifier in cell cultures.
- Claim:
4. The peptide, according to claim 1 , wherein said peptide is a membrane ionic permeability modifier of neurons in a primary culture.
- Claim:
5. A pharmaceutical composition useful for modifying neural membrane permeability wherein the active principle is a peptide according to claim 1 , in an effective amount to modify the neural membrane permeability along with a pharmaceutically acceptable carrier or vehicle.
- Claim:
6. The pharmaceutical composition according to claim 5 , wherein said peptide has selective antagonism towards the NMDA receptor GluN2B subunit.
- Claim:
7. The pharmaceutical composition according to claim 5 , wherein said peptide is a membrane ionic permeability modifier of neurons in a primary culture.
- Claim:
8. An artificially designed 17 amino acid-long peptide, wherein said peptide has the following hydrophilic amino acid sequence: GEDDYQDAQDLIRDKSN (SEQ ID NO: 3); has a molecular formula of C 80 H 124 N 24 O 35 ; a molecular weight of 1981.99 g/Mol; and isoelectric point of 3.90 and an average hydropathicity (GRAVY) of −1.900.
- Claim:
9. The peptide according to claim 8 , wherein said peptide has selective antagonism towards the NMDA receptor GluN2B and GluN2A subunits.
- Claim:
10. The peptide, according to claim 8 , wherein said peptide is a membrane ionic permeability modifier in cell cultures.
- Claim:
11. The peptide, according to claim 8 , wherein said peptide is a membrane ionic permeability modifier of neurons in a primary culture.
- Claim:
12. A pharmaceutical composition useful for modifying neural membrane permeability wherein the active principle is a peptide according to claim 8 , in an effective amount to modify the neural membrane permeability along with a pharmaceutically acceptable carrier or vehicle.
- Claim:
13. The pharmaceutical composition according to claim 12 , wherein said peptide has selective antagonism towards the NMDA receptor GluN2B and GluN2A subunits.
- Claim:
14. The pharmaceutical composition according to claim 12 , wherein said peptide is a membrane ionic permeability modifier in cell cultures.
- Patent References Cited:
5830998 November 1998 Maccecchini
2003/0134799 July 2003 Maccecchini
2003/0144210 July 2003 Olivera
2003/0194729 October 2003 Abogadie
- Primary Examiner:
Ulm, John D
- Attorney, Agent or Firm:
Angres, Isaac
- Accession Number:
edspgr.10689418
_0.png)
Processing Request
No Comments.